Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Janssen Pharmaceuticals
Biotech
J&J drops Addex epilepsy drug after reviewing phase 2 failure
After mulling the data from a failed trial, J&J has decided to halt development of its Addex-partnered epilepsy drug, Fierce Biotech has learned.
James Waldron
Jul 18, 2024 5:17am
Addex's Janssen-partnered epilepsy drug fails phase 2 trial
Apr 29, 2024 8:44am
Cidara regains rights to flu med from Janssen, divests Rezzayo
Apr 24, 2024 4:05pm
MeiraGTx gifts last of gene therapy rights to J&J for $415M
Dec 21, 2023 10:14am
SU2C gives out 7 grants to boost diversity in cancer trials
Sep 26, 2023 11:01am
J&J's multiple myeloma combo produces 96% Carvykti-like response
Jun 5, 2023 2:16pm
